Your browser doesn't support javascript.
loading
The effectiveness of adjuvant treatment approaches for resectable esophageal cancer: A single-center experience.
Algin, Efnan; Esen, Selin Akturk; Acikgoz, Yusuf; Bal, Oznur.
Afiliación
  • Algin E; Department of Medical Oncology, University of Health Sciences, Ankara City Hospital, Ankara, Turkey.
  • Esen SA; Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey.
  • Acikgoz Y; Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey.
  • Bal O; Department of Medical Oncology, University of Health Sciences, Ankara City Hospital, Ankara, Turkey.
J Cancer Res Ther ; 19(7): 2018-2024, 2023 Oct 01.
Article en En | MEDLINE | ID: mdl-38376312
ABSTRACT
AIMS AND

BACKGROUND:

In general, neoadjuvant treatment is the standard for clinical stage II/III esophageal cancer (EC), whereas the effect of adjuvant treatment on survival still remains controversial. The aim of this study was to investigate the efficacy of adjuvant treatment modalities on the survival of EC patients. PATIENTS AND

METHODS:

A total of 63 patients with stage II-IVA EC who had undergone curative surgery between the years 2002 and 2020 were included in the study. Patients' data were retrospectively collected from oncologic follow-up files. Various treatment regimens were administered during this period, including chemotherapy and chemoradiotherapy.

RESULTS:

The median age was 56 years (24-73), and the number of males was slightly higher than females (male/female 33/30). While 32 (51%) patients received postoperative adjuvant treatment, the remaining 31 (49%) patients underwent surgery alone. The median overall survival (OS) was 45.9 months (95% confidence interval [CI] 25.1-66.8) in patients receiving adjuvant therapy and 37.6 months (95% CI 20.9-54.4) in patients not receiving adjuvant therapy. The 8.3-month survival difference was statistically insignificant (P = 0.54). The 1-, 3-, and 5-year OS rates were 87.5% versus 77.4%, 58.4% versus 51.6%, and 40.8% versus 27.6% for patients with and without adjuvant therapy, respectively. Pathological stage (P = 0.028) and lymph node status (P = 0.044) were significant prognostic factors for survival.

CONCLUSIONS:

This study did not support the benefit of adjuvant treatment compared with surgery alone in completely resected EC patients. The reason for this result may be related to the small sample size and different treatment regimens due to the change in treatment options over time.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Esofágicas / Adenocarcinoma Límite: Female / Humans / Male / Middle aged Idioma: En Revista: J Cancer Res Ther Asunto de la revista: NEOPLASIAS / TERAPEUTICA Año: 2023 Tipo del documento: Article País de afiliación: Turquía Pais de publicación: India
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Esofágicas / Adenocarcinoma Límite: Female / Humans / Male / Middle aged Idioma: En Revista: J Cancer Res Ther Asunto de la revista: NEOPLASIAS / TERAPEUTICA Año: 2023 Tipo del documento: Article País de afiliación: Turquía Pais de publicación: India